The lack effect of food on the bioavailability of nefazodone tablets

Biopharmaceutics and Drug Disposition

Volumn 17, Issue 2, 1996, Pages 135-143

  Dockens, R C ^a   Greene, D S ^a   Barbhaiya, R H ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Food effects; Nefazodone

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; DRUG METABOLITE; HYDROXYNEFAZODONE; NEFAZODONE; TRIAZOLEDIONE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; FOOD DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DIETARY FATS; HUMANS; MALE; REFERENCE VALUES; TABLETS; TRIAZOLES;

EID: 0029883199     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199603)17:2<135::AID-BDD947>3.0.CO;2-K     Document Type: Article

References (26)

1. J. P. Feigher, R. Pambakian, R. C. Fowler, W. F. Boyer and M. F. D'Amico, A comparison of nefazodone, imipramine and placebo in patients with moderate to severe depression. Psychopharmacol. Bull., 25, 219-221 (1989).
2. A. S. Eison, M. S. Eison, J. R. Toprrente, R. N. Wright and F. D. Yocca, Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol. Bull., 26, 311-315 (1990).
3. D. P. Taylor, D. W. Smith, D. K. Hyslop, L. A. Riblet, and D. L. Temple, Jr., Receptor binding and atypical antidepressant drug discovery. In Receptor Binding in Drug Research, R. A. O'Brien (Ed.), Marcel Dekker, New York, 1986, pp. 151-165.
4. D. K. Hyslop, L. E. Allen, and D. P. Taylor, Triazolo antidepressants do not inhibit monoamine oxidase. Drug Rev. Res., 12, 77-79 (1988).
5. S. Kaul, U. A. Shukla and R. H. Barbhaiya, Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. J. Clin. Pharmacol., 35, 830-839 (1995).
6. R. F. Mayol, C. A. Cole, G. M. Luke, K. L. Colson, and E. H. Kerns, Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab. Disposit., 22, 304-311 (1994).
7. R. H. Barbhaiya, U. A. Shukla and D. S. Greene, Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment. Eur. J. Clin. Pharmacol., in press.
8. R. H. Barbhaiya, M. E. Brady, U. A. Shukla and D. S. Greene, Steady-state pharmacokinetics of nefazodone in subjects with normal and impaired renal function. Eur. J. Clin. Pharmacol., in press.
9. R. H. Barbhaiya, U. A. Shukla, S. Chandra, M. S. Nataragan, D. A. Behr, D. S. Greene and S. M. Sainati, Single and multiple dose pharmacokinetics of nefazodone in subjects with hepatic cirrhosis. Clin. Pharmacol. Ther., in press.
10. R. C. Dockens, D. S. Greene and R. H. Barbhaiya, Investigation of the effect of nefazodone on the pharmacokinetics and pharmacodynamics of the theophylline in patients with chronic obstructive pulmonary disease. J. Clin. Pharmacol., in press.
11. P. H. Marathe, P. Chaikin, D. S. Greene and R. H. Barbhaiya, Comparison of the steady state pharmacokinetics and pharmacodynamics of nefazodone after administering once daily in the morning or evening and twice daily. J. Clin. Pharmcol., in press.
12. A. Melander, Influence of food on the bioavailability of drugs. Clin. Pharmacokinet., 3, 337-351 (1978).
13. A. Melander, K. Danielson, B. Schersten and E. Wahlin. Enhancement of the bioavailability of propranolol and metoprolol by food. Clin. Pharm. Ther., 22, 108-112 (1977).
14. H. Liedholm, E. Wahlin-Boll and A. Melander, Mechanisms and variations in the food effect on propranolol bioavailability. Eur. J. Clin. Pharmacol., 38, 469-475 (1990).
15. R. D. Toothaker, E. J. Randinitis, C. Nelson, A. W. Kinkel and J. R. Goulet, The influence of food on the oral absorption of bevantolol, J. Clin. Pharmacol., 27, 297-299 (1987).
16. A. Melander, P. Stenbert, H. Liedhohn et al., Food-induced reduction in bioavailability of atenolol. Eur. H. Clin. Pharmacol., 16, 327-330 (1979).
17. A. B. Buch, D. S. Greene and R. H. Barbhaiya, Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. Br. J. Clin. Pharmacol., Submitted.
18. B. Schmid, M. D. Bircher, R. Preisig and A. Kupfer, Polymorphic dextromethorphan metabolism: co-segregation of oxidative o-demethylation with debrisoquin hydroxylation. Clin. Pharmacol. Ther., 38, 618-624 (1985).
19. J. E. Franc, G. F. Duncan, R. H. Farmen and K. A. Pittman, High performance liquid chromatographic method for the determination of nefazodone and its metabolites in human plasma using laboratory robotics. J. Chromatogr., 540, 129-138 (1991).
20. G. E. P. Box and D. R. Cox, Analysis of transformations. J. R. Stat. Soc.,. B, 26, 211-252 (1964).
21. M. Hollander and D. A. Wolfe, Nonparametric Statistical Methods, Wiley, New York, 1973, pp. 27-28.
22. 14C]nefazodone in humans. Drug Metab. Disposit., Submitted.
23. C. B. Nemeroff, Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression. J. Clin. Psychopharmacol., 13 (6 suppl. 2), 10S-17S (1993).
24. S. H. Ingwersen, T. G. Mant and J. J. Larsen, Food intake increases the relative oral bioavailability of vanoxerine. Br. J. Clin. Pharmacol., 35, 308-310 (1993).
25. J. Van Harten, P. Van Bemmel, M. R. Dobrinska, R. K. Ferguson and M. Raghoebar, Bioavailability of fluvoxamine given with and without food. Biopharm. Drug Disposit., 12, 571-576 (1991).
26. R. H. Barbhaiya, U. A. Shukla, P. Chaikin and D. S. Greene, Time to steady state after escalation/de-escalation of nefazodone BID doses. Eur. J. Clin. Pharmacol., in press.